Hensley, Martee Leigh

Publications

Sort by

Co-Author Network

selected publications

State of the science: Uterine sarcomas: From pathology to practice. Gynecologic oncology. 2020 Editorial Article GET IT
Times cited: 4
Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 38
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. Cancer. 2019 Academic Article GET IT
Times cited: 30
Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. Gynecologic oncology. 2019 Academic Article GET IT
Times cited: 6
Reply to F. Tomao et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Letter GET IT
A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors. The oncologist. 2018 Academic Article GET IT
Times cited: 11
A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2018 Academic Article GET IT
Times cited: 5
Brain structure and function in patients with ovarian cancer treated with first-line chemotherapy: a pilot study. Brain imaging and behavior. 2017 Academic Article GET IT
Times cited: 30
Difficult Choices in Stage I Uterine Leiomyosarcoma- it's okay to "stand there". Gynecologic oncology. 2017 Editorial Article GET IT
Times cited: 5
YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy. Gynecologic oncology. 2017 Academic Article GET IT
Times cited: 22
Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic oncology. 2017 Academic Article GET IT
Times cited: 17
Novel High-grade Endometrial Stromal Sarcoma: A Morphologic Mimicker of Myxoid Leiomyosarcoma. 2017 GET IT
Times cited: 92
A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. Gynecologic oncology. 2016 Academic Article GET IT
Times cited: 15
Low-Volume Lymph Node Metastasis Discovered During Sentinel Lymph Node Mapping for Endometrial Carcinoma. Annals of surgical oncology. 2015 Academic Article GET IT
Times cited: 100
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 563
What Do You Say When She Is No Longer Living With Cancer?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 1
Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 98
Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcome. Neoplasia (New York, N.Y.). 2015 Academic Article GET IT
Times cited: 35
Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. European journal of cancer (Oxford, England : 1990). 2014 Review GET IT
Times cited: 89
Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2014 Review GET IT
Times cited: 47
Management of advanced uterine leiomyosarcoma. Current opinion in oncology. 2014 Review GET IT
Times cited: 15
A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecologic oncology. 2014 Academic Article GET IT
Times cited: 27
Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 31
Redefining stage I endometrial cancer: incorporating histology, a binary grading system, myometrial invasion, and lymph node assessment. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2013 Academic Article GET IT
Times cited: 17
Treatment outcomes in completely resected stage I to stage IV uterine carcinosarcoma with rhabdomyosarcoma differentiation. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2013 Academic Article GET IT
Times cited: 3
Classification and regression tree (CART) analysis of endometrial carcinoma: Seeing the forest for the trees. Gynecologic oncology. 2013 Academic Article GET IT
Times cited: 81
Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2013 Academic Article GET IT
Times cited: 196
Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2013 Academic Article GET IT
Times cited: 35
External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma. Cancer. 2013 Academic Article GET IT
Times cited: 51
Radiation therapy for epithelial ovarian cancer brain metastases: clinical outcomes and predictors of survival. Radiation oncology (London, England). 2013 Academic Article GET IT
Times cited: 18
Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer. 2013 Academic Article GET IT
Times cited: 141
Impact of incorporating an algorithm that utilizes sentinel lymph node mapping during minimally invasive procedures on the detection of stage IIIC endometrial cancer. Gynecologic oncology. 2013 Academic Article GET IT
Times cited: 56
Management of uterine adenosarcomas with and without sarcomatous overgrowth. Gynecologic oncology. 2012 Academic Article GET IT
Times cited: 63
Location of disease in patients who die from endometrial cancer: a study of 414 patients from a single institution. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2012 Academic Article GET IT
Times cited: 14
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 209
High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes. Gynecologic oncology. 2012 Academic Article GET IT
Times cited: 68
Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer. Gynecologic oncology. 2012 Academic Article GET IT
Times cited: 39
Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis. Gynecologic oncology. 2012 Academic Article GET IT
Times cited: 51
Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2012 Academic Article GET IT
Times cited: 2
Patterns of recurrence in 1988 FIGO stage IC endometrioid endometrial cancer. Gynecologic oncology. 2011 Academic Article GET IT
Times cited: 15
Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma. Gynecologic oncology. 2011 Academic Article GET IT
Times cited: 65
Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma. Investigational new drugs. 2011 Academic Article GET IT
Times cited: 8
Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 38
"Low-grade leiomyosarcoma" and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas. The American journal of surgical pathology. 2011 Academic Article GET IT
Times cited: 41
A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study. Gynecologic oncology. 2011 Academic Article GET IT
Times cited: 83
Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study. Cancer. 2011 Academic Article GET IT
Times cited: 16
A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors. Investigational new drugs. 2011 Academic Article GET IT
Times cited: 6
Role of chemotherapy and biomolecular therapy in the treatment of uterine sarcomas. Best practice & research. Clinical obstetrics & gynaecology. 2011 Review GET IT
Times cited: 26
A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma. Cancer. 2011 Academic Article GET IT
Times cited: 112
Sentinel lymph node mapping for endometrial cancer improves the detection of metastatic disease to regional lymph nodes. Gynecologic oncology. 2011 Academic Article GET IT
Times cited: 125
Histopathologic prognostic factors in stage I leiomyosarcoma of the uterus: a detailed analysis of 27 cases. 2011 GET IT
Times cited: 42
The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered?. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2011 Academic Article GET IT
Times cited: 48
Big costs for little gain in ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Editorial Article GET IT
Times cited: 26
Incidence of lymph node and adnexal metastasis in endometrial stromal sarcoma. Gynecologic oncology. 2011 Academic Article GET IT
Times cited: 46
Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 147
Cognitive functions in long-term survivors of ovarian cancer. Gynecologic oncology. 2010 Academic Article GET IT
Times cited: 26
Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas. Current opinion in oncology. 2010 Review GET IT
Times cited: 27
A step forward for two-step screening for ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Editorial Article GET IT
Times cited: 12
A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. Gynecologic oncology. 2010 Academic Article GET IT
Times cited: 88
Paraneoplastic opsoclonus-myoclonus syndrome secondary to immature ovarian teratoma. 2010 GET IT
Times cited: 16
Optimal management of uterine leiomyosarcoma. Expert review of anticancer therapy. 2010 Academic Article GET IT
Times cited: 22
Consolidation strategies in ovarian cancer: observations for future clinical trials. Gynecologic oncology. 2010 Academic Article GET IT
Times cited: 9
The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. Gynecologic oncology. 2009 Academic Article GET IT
Times cited: 41
Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecologic oncology. 2009 Academic Article GET IT
Times cited: 79
Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecologic oncology. 2009 Academic Article GET IT
Times cited: 79
The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. Gynecologic oncology. 2009 Academic Article GET IT
Times cited: 155
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 459
Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 111
Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541. Cancer. 2009 Academic Article GET IT
Times cited: 16
Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. Gynecologic oncology. 2009 Academic Article GET IT
Times cited: 184
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 438
Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804. Psycho-oncology. 2008 Academic Article GET IT
Times cited: 26
A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 12
A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. Gynecologic oncology. 2008 Academic Article GET IT
Times cited: 62
What is the incidence of isolated paraaortic nodal recurrence in grade 1 endometrial carcinoma?. Gynecologic oncology. 2008 Academic Article GET IT
Times cited: 30
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecologic oncology. 2008 Academic Article GET IT
Times cited: 67
Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecologic oncology. 2008 Academic Article GET IT
Times cited: 276
Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 93
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecologic oncology. 2008 Academic Article GET IT
Times cited: 206
A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008 Academic Article GET IT
Times cited: 96
A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission. European journal of gynaecological oncology. 2008 Academic Article GET IT
Times cited: 16
Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2007 Academic Article GET IT
Times cited: 143
Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 123
Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials. Gynecologic oncology. 2007 Academic Article GET IT
Times cited: 30
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 584
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. Investigational new drugs. 2007 Academic Article GET IT
Times cited: 16
Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2007 Academic Article GET IT
Times cited: 12
Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 91
A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2007 Academic Article GET IT
Times cited: 12
Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2007 Academic Article GET IT
Times cited: 52
Primary retroperitoneal lymphangioleiomyomatosis in a postmenopausal woman: a case report and review of the literature. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2007 Review GET IT
Times cited: 18
The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions. Gynecologic oncology. 2006 Academic Article GET IT
Times cited: 50
Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecologic oncology. 2006 Academic Article GET IT
Times cited: 55
CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecologic oncology. 2006 Academic Article GET IT
Times cited: 61
Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 64
What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecologic oncology. 2006 Academic Article GET IT
Times cited: 529
Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study. Gynecologic oncology. 2006 Academic Article GET IT
Times cited: 56
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Annals of oncology : official journal of the European Society for Medical Oncology. 2006 Academic Article GET IT
Times cited: 25
Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning. Gynecologic oncology. 2006 Academic Article GET IT
Times cited: 27
Topotecan and liposomal doxorubicin in recurrent ovarian cancer: is sequence important?. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2006 Academic Article GET IT
Times cited: 5
Rare uterine cancers. The Lancet. Oncology. 2005 Review GET IT
Times cited: 99
Transfusion utilization during adnexal or peritoneal cancer surgery: effects on symptomatic venous thromboembolism and survival. Gynecologic oncology. 2005 Academic Article GET IT
Times cited: 54
Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up. Cancer. 2005 Academic Article GET IT
Times cited: 20
Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. British journal of clinical pharmacology. 2005 Academic Article GET IT
Times cited: 103
Patient online self-reporting of toxicity symptoms during chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 237
Economic outcomes of breast cancer survivorship: CALGB study 79804. Breast cancer research and treatment. 2005 Academic Article GET IT
Times cited: 36
Cancer screening: how good is good enough?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Editorial Article GET IT
Times cited: 6
Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer. 2004 Academic Article GET IT
Times cited: 120
Early detection and prognosis of ovarian cancer using serum YKL-40. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 119
Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571). Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 21
Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer. Gynecologic oncology. 2004 Academic Article GET IT
Times cited: 6
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. The New England journal of medicine. 2003 Academic Article GET IT
Times cited: 1085
Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecologic oncology. 2003 Academic Article GET IT
Times cited: 39
Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature. American journal of clinical oncology. 2003 Review GET IT
Times cited: 27
Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life. Gynecologic oncology. 2003 Academic Article GET IT
Times cited: 35
Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 161
Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecologic oncology. 2003 Academic Article GET IT
Times cited: 118
Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Seminars in hematology. 2003 Review GET IT
Times cited: 154
Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. Gynecologic oncology. 2002 Academic Article GET IT
Times cited: 75
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 408
2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. 2002 GET IT
Times cited: 238
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 587
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. The New England journal of medicine. 2002 Academic Article GET IT
Times cited: 1161
Epithelial ovarian cancer. Current treatment options in oncology. 2002 Review GET IT
Times cited: 25
Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. 2002 GET IT
Times cited: 100
Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 403
Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 96
Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 111
Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic oncology. 2001 Academic Article GET IT
Times cited: 215
The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients. Gynecologic oncology. 2001 Academic Article GET IT
Times cited: 20
Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer. Gynecologic oncology. 2001 Academic Article GET IT
Times cited: 19
Paclitaxel-based chemotherapy in carcinoma of the fallopian tube. Gynecologic oncology. 2001 Academic Article GET IT
Times cited: 55
Uterine/female genital sarcomas. Current treatment options in oncology. 2000 Review GET IT
Times cited: 11
Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: a critique. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Letter GET IT
Times cited: 7
Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Times cited: 53
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. 1999 GET IT
Times cited: 325
Implementation of disease management guidelines in patients with advanced ovarian cancer. Seminars in oncology. 1999 Review GET IT
Times cited: 2
Fertility and pregnancy after adjuvant chemotherapy for breast cancer. Critical reviews in oncology/hematology. 1998 Review GET IT
Times cited: 29
Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma. Investigational new drugs. 1996 Academic Article GET IT
Times cited: 9
Evidence for a bioactive clonidine-displacing substance in peripheral tissues and serum. Biochemical pharmacology. 1992 Academic Article GET IT
Times cited: 32
Clonidine-displacing substance is present in peripheral tissues of the rat. American journal of hypertension. 1989 Academic Article GET IT
Times cited: 17

more ...

less ...

Background

education and training

M.Sc., Harvard School of Public Health 1998
M.D., Duke University School of Medicine 1989
A.B., Duke University 1985

Contact

full name

Martee Leigh Hensley

VIVO Weill Cornell Medical College

Martee Leigh Hensley Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name